MX2019000180A - Composiciones de células t para la inmunoterapia. - Google Patents

Composiciones de células t para la inmunoterapia.

Info

Publication number
MX2019000180A
MX2019000180A MX2019000180A MX2019000180A MX2019000180A MX 2019000180 A MX2019000180 A MX 2019000180A MX 2019000180 A MX2019000180 A MX 2019000180A MX 2019000180 A MX2019000180 A MX 2019000180A MX 2019000180 A MX2019000180 A MX 2019000180A
Authority
MX
Mexico
Prior art keywords
immunotherapy
cell compositions
compositions
cell
reactivity
Prior art date
Application number
MX2019000180A
Other languages
English (en)
Inventor
E Slanetz Alfred
Y NAKAGAWA Terry
A HERMAN Marissa
Original Assignee
Geneius Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneius Biotechnology Inc filed Critical Geneius Biotechnology Inc
Publication of MX2019000180A publication Critical patent/MX2019000180A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

El invento se relaciona con composiciones que comprenden una población heterogénea de células T reactivas a antígenos seleccionados que son útiles para la inmunoterapia adoptiva y métodos para elaborar las composiciones de células T.
MX2019000180A 2016-06-28 2017-06-28 Composiciones de células t para la inmunoterapia. MX2019000180A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662355533P 2016-06-28 2016-06-28
US201662355458P 2016-06-28 2016-06-28
US201662355506P 2016-06-28 2016-06-28
PCT/US2017/039846 WO2018005712A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Publications (1)

Publication Number Publication Date
MX2019000180A true MX2019000180A (es) 2019-11-05

Family

ID=60787739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000180A MX2019000180A (es) 2016-06-28 2017-06-28 Composiciones de células t para la inmunoterapia.

Country Status (11)

Country Link
US (2) US20200237819A1 (es)
EP (1) EP3487990A4 (es)
JP (2) JP7034955B2 (es)
KR (1) KR20190037243A (es)
CN (1) CN109715788A (es)
AU (2) AU2017290119A1 (es)
CA (1) CA3068387A1 (es)
IL (1) IL263896A (es)
MX (1) MX2019000180A (es)
SG (1) SG11201811745UA (es)
WO (1) WO2018005712A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101413519B1 (ko) 2013-05-15 2014-07-02 전태화 휴즈의 리드선 절단 및 절곡장치
WO2016154112A1 (en) * 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CN110199016A (zh) 2016-11-17 2019-09-03 艾欧凡斯生物治疗公司 残余肿瘤浸润淋巴细胞及其制备和使用方法
EP3565586A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11793867B2 (en) * 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
JP7198602B2 (ja) * 2018-07-11 2023-01-04 カワサキモータース株式会社 自動二輪車
WO2020027094A1 (ja) * 2018-07-31 2020-02-06 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
US20210214686A1 (en) * 2018-07-31 2021-07-15 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (turics)
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
KR20210043622A (ko) * 2018-08-10 2021-04-21 주식회사 유틸렉스 암항원 특이적 세포독성 t세포
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
AU2019403263A1 (en) * 2018-12-18 2021-07-01 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype
WO2020146434A2 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
WO2020168250A1 (en) * 2019-02-14 2020-08-20 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
EP3976068A4 (en) * 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
EP4021180A4 (en) * 2019-08-29 2023-11-08 Board of Regents, The University of Texas System CELL CRYOPRESERVATION MEDIUM
JP2023504042A (ja) * 2019-11-27 2023-02-01 ミスト セラピューティクス リミテッド ライアビリティ カンパニー 調節物質を使用した腫瘍反応性ｔ細胞組成物の生成方法
JP2023551819A (ja) * 2020-11-25 2023-12-13 ジーニアス・バイオテクノロジー・インコーポレイテッド 抗原特異的ｔ細胞並びにその作製及び使用方法
CN113481157B (zh) * 2021-07-21 2023-03-17 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
CN113564116B (zh) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN113512529B (zh) * 2021-07-21 2022-11-25 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
IL310696A (en) * 2021-09-08 2024-04-01 Ksq Therapeutics Inc Lymphocyte intensity test
WO2023060195A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
JP2023064787A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の品質評価方法、および当該方法に用いる試薬
WO2023178140A2 (en) * 2022-03-18 2023-09-21 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4601166B2 (ja) * 1998-05-11 2010-12-22 ミルテニィ バイオテック ゲーエムベーハー 抗原特異的ｔ細胞の直接的選択方法
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
HUE024541T2 (hu) * 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
RU2012111349A (ru) * 2009-08-24 2013-10-27 Байлор Колледж Оф Медсин Генерация линий ctl со специфичностью против множества опухолевых антигенов или множества вирусов
US9114100B2 (en) * 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
CN103906531A (zh) * 2011-05-26 2014-07-02 金纽斯生物科技投资有限责任公司 调节的免疫优势疗法
CA2996848C (en) * 2014-09-04 2021-01-05 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion

Also Published As

Publication number Publication date
AU2023254998A1 (en) 2023-11-16
SG11201811745UA (en) 2019-01-30
US20230145991A1 (en) 2023-05-11
AU2017290119A1 (en) 2019-01-24
JP2022066355A (ja) 2022-04-28
KR20190037243A (ko) 2019-04-05
CN109715788A (zh) 2019-05-03
WO2018005712A1 (en) 2018-01-04
JP7034955B2 (ja) 2022-03-14
IL263896A (en) 2019-01-31
JP2019519246A (ja) 2019-07-11
US20200237819A1 (en) 2020-07-30
EP3487990A1 (en) 2019-05-29
CA3068387A1 (en) 2018-01-04
EP3487990A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
MA39819A (fr) Méthodes et compositions d'immunomodulation
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
MX2020004229A (es) Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
NZ726989A (en) Improved t cell compositions
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
EP3510145A4 (en) IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
PH12015502271B1 (en) Compositions and methods for immunotherapy
MY175869A (en) Compositions and methods for immunotherapy
MX2020010040A (es) Anticuerpos que se unen a tau y usos de los mismos.
MX2018002849A (es) Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
IL282637A (en) Methods for allogeneic transplantation of hematopoietic stem cells
IL273452A (en) Cell preparations comprising antigen-specific T cells for adoptive therapy
EP3532078A4 (en) ARTIFICIAL ANTIGEN PRESENT CELLS USED FOR THE EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
MX2020012893A (es) Formulaciones de proteinas.
WO2018015810A3 (en) Multivirus-specific t cell immunotherapy
MX2022000516A (es) Metodos relacionados con celulas pluripotentes.
EP4248991A3 (en) Methods and materials for expanding antigen-specific t cells in culture
IL290109A (en) Cells for enhanced immune healing and their uses
EA201990101A1 (ru) Композиции т-клеток для иммунотерапии